Great concern over scientific misconduct has been expressed by both the scientific community and the public at large. In Japan, repeated media coverage in 2014 - 2015 of two incidents, namely the fraudulent data for the antihypertensive drug Diovan marketed by Novartis, and the STAP cell scandal, evoked widespread concern. In my lecture, I will analyze some misconduct cases and summarize lessons learnt from them.

Date: Wednesday, March 22, 2017
Time: 16:30 – 17:30
Venue: 1F Auditorium, IIIS Building